GRAIL, Inc.
GRAIL, Inc. (GRAL) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · GRAL · as of Jun 8, 2026
Key Statistics
Explore GRAIL, Inc. Data
gral stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 6 · Buy rate: 66.7%
The GRAL analyst consensus is Buy, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $73.43, representing +19.36% upside from the current price of $61.52.
Competitors & Peers
gral competitorsGRAL
AAPG
APGE
CELC
CNTA
DYNStock Performance
Full HistoryAbout GRAIL, Inc.
GRAIL, Inc. is a biotechnology firm dedicated to advancing innovations for detecting cancer at its earliest stages. Among its key offerings is Galleri, a screening test designed for individuals aged 5…
what is grail, inc. · gral stock overview · grail, inc. company profile · who is grail, inc. ceo · gral NASDAQ · grail, inc. headquarters · grail, inc. business segments
About Stock Overview & Key Data
GRAIL, Inc. (GRAL) is a Healthcare company in the Medical - Diagnostics & Research industry, listed on NASDAQ since Jun 12, 2024. As of the latest trading session, GRAL stock price is $61.52, with a market capitalization of $2.6B. The stock has returned +50.14% over the past 12 months and -29.78% year-to-date.
According to 6 Wall Street analysts, the consensus rating for GRAIL, Inc. stock is Buy, with an average 12-month price target of $73.43. In fiscal year 2025, GRAIL, Inc. reported revenue of $147.2M and net income of -$408.4M. For detailed data — including GRAIL, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, GRAIL, Inc. (GRAL) stock price is $61.52. The stock is traded on NASDAQ under the ticker symbol GRAL. The 52-week range is $29.95 – $118.84.